Q1 Earnings Estimate for Albemarle Issued By Scotiabank

Albemarle Co. (NYSE:ALB) – Equities research analysts at Scotiabank issued their Q1 2025 earnings per share estimates for shares of Albemarle in a research note issued on Tuesday, February 18th. Scotiabank analyst B. Isaacson forecasts that the specialty chemicals company will post earnings per share of ($0.14) for the quarter. Scotiabank currently has a “Sector Perform” rating and a $75.00 target price on the stock. The consensus estimate for Albemarle’s current full-year earnings is $0.45 per share. Scotiabank also issued estimates for Albemarle’s FY2026 earnings at $2.51 EPS.

ALB has been the topic of a number of other reports. Evercore ISI lowered shares of Albemarle from an “outperform” rating to an “inline” rating in a research note on Wednesday, February 5th. Robert W. Baird reduced their price target on shares of Albemarle from $103.00 to $92.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 12th. UBS Group reduced their price target on shares of Albemarle from $99.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Morgan Stanley dropped their target price on shares of Albemarle from $73.00 to $68.00 and set an “underweight” rating for the company in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of Albemarle from $109.00 to $105.00 in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $109.68.

Albemarle Trading Down 1.5 %

Shares of Albemarle stock opened at $81.26 on Thursday. The firm has a market capitalization of $9.55 billion, a PE ratio of -7.26, a P/E/G ratio of 11.64 and a beta of 1.59. Albemarle has a twelve month low of $71.97 and a twelve month high of $143.19. The firm’s 50-day moving average price is $86.93 and its 200 day moving average price is $92.05. The company has a current ratio of 1.95, a quick ratio of 1.19 and a debt-to-equity ratio of 0.39.

Albemarle (NYSE:ALB) last posted its earnings results on Wednesday, February 12th. The specialty chemicals company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.49). Albemarle had a negative net margin of 21.93% and a negative return on equity of 1.72%.

Insider Buying and Selling

In related news, CEO J Kent Masters sold 2,525 shares of the business’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $101.12, for a total value of $255,328.00. Following the completion of the sale, the chief executive officer now directly owns 73,747 shares of the company’s stock, valued at $7,457,296.64. The trade was a 3.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.38% of the company’s stock.

Institutional Investors Weigh In On Albemarle

Institutional investors and hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of Albemarle by 38.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,020,590 shares of the specialty chemicals company’s stock valued at $96,660,000 after buying an additional 282,194 shares during the last quarter. Pacer Advisors Inc. raised its holdings in shares of Albemarle by 71.5% in the fourth quarter. Pacer Advisors Inc. now owns 14,948 shares of the specialty chemicals company’s stock valued at $1,287,000 after buying an additional 6,234 shares during the last quarter. Bristlecone Advisors LLC raised its holdings in shares of Albemarle by 20.5% in the fourth quarter. Bristlecone Advisors LLC now owns 28,824 shares of the specialty chemicals company’s stock valued at $2,481,000 after buying an additional 4,899 shares during the last quarter. Empower Advisory Group LLC raised its holdings in shares of Albemarle by 28.7% in the third quarter. Empower Advisory Group LLC now owns 705,719 shares of the specialty chemicals company’s stock valued at $66,839,000 after buying an additional 157,319 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its holdings in shares of Albemarle by 28.5% in the third quarter. Nomura Asset Management Co. Ltd. now owns 423,049 shares of the specialty chemicals company’s stock valued at $40,067,000 after buying an additional 93,718 shares during the last quarter. 92.87% of the stock is owned by hedge funds and other institutional investors.

About Albemarle

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.